October – December, 2025
October:
October 2025 marked the start of a new journey with the BIOCORE project — a different kind of initiative, focused not only on scientific excellence but on bringing research closer to the market and real clinical application.
🦴 Within BIOCORE, we work on BIOmaterials for Infection COntrol and fast bone tissue REgeneration, addressing a critical challenge in modern medicine: post-surgical infections and slow bone regeneration.
Within 12 months, BIOCORE will deliver:
✔️ Clinically relevant product design co-developed with medical professionals
✔️ A strengthened intellectual property portfolio, paving the way toward commercialization
✨ BIOCORE is about impact, translation, and real-world value – turning advanced biomaterials into better outcomes for patients.
November:
On 24 November 2025, the 1st Conference of the Biomedical and Photonics Research Platform for Innovative Products “BioPhoT”, titled “BioPhoT – Latvia’s Innovation Launchpad”, brought together industry representatives, science policy makers, and the scientific community. The conference showcased BioPhoT’s research and innovation projects, highlighted future development plans, and presented international success stories from the biomedical and photonics sectors.
The event fostered expert discussions on the role of innovation in national development and economic growth. Participants explored 40 research and innovation projects, and the best poster presentations were awarded in the categories “Biomedicine” and “Photonics”.
The conference united a broad range of stakeholders – researchers, industry leaders, startup founders, policymakers, university leadership, innovation experts, and public sector representatives – enabling cross-sector dialogue across biomedicine, photonics, manufacturing, biotechnology, data analytics, and innovation governance, and strengthening pathways from academia to commercialization.
December:
In December 2025, the BIOCORE team took an important step toward future market readiness by engaging with the State Agency of Medicines of the Republic of Latvia. This milestone focused on understanding the regulatory framework required to advance BIOCORE toward certification as a medical product.
The insights gained are now guiding the project’s next phases, ensuring that BIOCORE’s development aligns with regulatory expectations, quality standards, and long-term clinical applicability.
This marks a key step in BIOCORE’s journey from scientific innovation toward real-world medical impact.
